Rajeev Chillakuru
Keine laufenden Positionen mehr
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Leo Nelson Hopkins | M | - |
State University of New York at Buffalo
| 35 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Timothy Shannon | M | 65 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 7 Jahre |
| Jonathan Rothberg | M | 60 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 11 Jahre |
| Gregory T. Went | M | 60 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 7 Jahre |
| Jonathan M. Pfohl | M | 57 |
State University of New York at Buffalo
| 5 Jahre |
| Timothy Murphy | M | 60 |
State University of New York at Buffalo
| 6 Jahre |
| Karim Suwwan de Felipe | M | - |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 1 Jahre |
| Maddi Lynn Dessner | F | - |
State University of New York at Buffalo
| 5 Jahre |
| John Holger Forsgren | M | 78 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 7 Jahre |
| Jonathan Root | M | - |
State University of New York at Buffalo
| 5 Jahre |
| Chris Thornberg | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Kimberly Muller | F | - |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 3 Jahre |
| Nan L. Haynes | F | - |
State University of New York at Buffalo
| 3 Jahre |
| Daniel Jean | M | - |
State University of New York at Buffalo
| 2 Jahre |
| D. Bruce Johnstone | M | - |
State University of New York at Buffalo
| 9 Jahre |
| Bradley Gayton | M | 61 |
State University of New York at Buffalo
| 3 Jahre |
| Larry Grosbaum | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Siu Lo Lam | M | 62 |
State University of New York at Buffalo
| 4 Jahre |
| Christopher Kern | M | 55 |
State University of New York at Buffalo
| 4 Jahre |
| Joe Levinson | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Anthony Dates | M | 58 |
State University of New York at Buffalo
| 4 Jahre |
| Seung-Won Kang | M | 59 |
State University of New York at Buffalo
| 1 Jahre |
| Mary E. Taylor | F | 65 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 5 Jahre |
| Yin Hoong Tseng | M | 62 |
State University of New York at Buffalo
| 4 Jahre |
| Steven Katz | M | - |
State University of New York at Buffalo
| 5 Jahre |
| Paul Kasinski | M | - |
State University of New York at Buffalo
| 2 Jahre |
| Michael Goodman | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Tong Zhao | M | 49 |
State University of New York at Buffalo
| 4 Jahre |
| John Anthony Pieroni | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Michael King | M | 55 |
State University of New York at Buffalo
| 1 Jahre |
| Siti Sarlina Binti Abdul Rahman | F | 55 |
State University of New York at Buffalo
| 4 Jahre |
| Parman Nataatmadja | M | - |
State University of New York at Buffalo
| 2 Jahre |
| Muhamadian | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Richard Lungen | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Michael L. Klawitter | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Johannes Halim | M | 55 |
State University of New York at Buffalo
| 4 Jahre |
| Kok Lim Law | M | 50 |
State University of New York at Buffalo
| 4 Jahre |
| Lawrence Tentor | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Yan Tian | M | - |
State University of New York at Buffalo
| 2 Jahre |
| Alan Klembczyk | M | 58 |
State University of New York at Buffalo
| 4 Jahre |
| Jianzhong Cha | M | 76 |
State University of New York at Buffalo
| 3 Jahre |
| Siew Fai Lim | M | 57 |
State University of New York at Buffalo
| 4 Jahre |
| Camille P. Wicher | M | - |
State University of New York at Buffalo
| 1 Jahre |
| Richard P. Lifton | M | 71 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 6 Jahre |
| Tsang-Bin Zeng | M | - |
State University of New York at Buffalo
| 3 Jahre |
| Andrew Cox | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Wendy A. Kellogg | M | - |
State University of New York at Buffalo
| 1 Jahre |
| Dave Kraus | M | - |
State University of New York at Buffalo
| 2 Jahre |
| Mark Sawicki | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Christopher K. McLeod | M | - |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | - |
| Bill B. Smith | M | 55 |
State University of New York at Buffalo
| 4 Jahre |
| William Ho | M | 48 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | - |
| Jim Morrow | M | 52 |
State University of New York at Buffalo
| 4 Jahre |
| Joanne Mcintosh | F | - |
State University of New York at Buffalo
| 4 Jahre |
| Lawrence Seth Winer | M | - |
State University of New York at Buffalo
| 4 Jahre |
| John E. Murphy | M | 76 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 4 Jahre |
| David Ebsworth | M | 69 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 5 Jahre |
| Richard S. Judson | M | 65 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 2 Jahre |
| Piero Bussani | M | 59 |
State University of New York at Buffalo
| 3 Jahre |
| Steven B. Sample | M | 83 |
State University of New York at Buffalo
| 9 Jahre |
| Michael McKenna | M | 61 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 10 Jahre |
| Ken Keyong Ren | M | 64 |
State University of New York at Buffalo
| 3 Jahre |
| Lawrence Somma | M | 57 |
State University of New York at Buffalo
| 2 Jahre |
| William F. Hahne | M | 70 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 2 Jahre |
| Darren Mitchel Sardoff | M | 57 |
State University of New York at Buffalo
| 4 Jahre |
| Scott Gerard | M | 56 |
State University of New York at Buffalo
| 4 Jahre |
| Cheryl A. Howe | F | - |
State University of New York at Buffalo
| 4 Jahre |
| Joseph Levinson | M | 48 |
State University of New York at Buffalo
| 4 Jahre |
| Paul R. Smith | M | - |
State University of New York at Buffalo
| 2 Jahre |
| Jonathan Chou | M | 60 |
State University of New York at Buffalo
| 4 Jahre |
| Hua Gang Zhang | M | 61 |
State University of New York at Buffalo
| 2 Jahre |
| James Mylock | M | 58 |
State University of New York at Buffalo
| 4 Jahre |
| Pascal Gaude | M | - |
State University of New York at Buffalo
| 4 Jahre |
| James Justin Palmisciano | M | 57 |
State University of New York at Buffalo
| 4 Jahre |
| Khaled Mohammed Oudeh Quran | M | 57 |
State University of New York at Buffalo
| 2 Jahre |
| Tiffanie Marie Fisher | F | - |
State University of New York at Buffalo
| 4 Jahre |
| Shoshana K. Loeb | M | - |
State University of New York at Buffalo
| 7 Jahre |
| Scott Silver | M | 64 |
State University of New York at Buffalo
| 4 Jahre |
| Nilesh Nanavati | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Martin J. Jasinski | M | - |
State University of New York at Buffalo
| 2 Jahre |
| Richard Safran | M | - |
State University of New York at Buffalo
| 4 Jahre |
| Lyn M. Dyster | M | - |
State University of New York at Buffalo
| 5 Jahre |
| Ping Li | M | 70 |
State University of New York at Buffalo
| 2 Jahre |
| Doug M. Druzbik | M | - |
State University of New York at Buffalo
| 3 Jahre |
| Mark Barberio | M | 61 |
State University of New York at Buffalo
| 2 Jahre |
| Vimal Mehta | M | 63 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | 6 Jahre |
| Vincent Celestino | M | - |
State University of New York at Buffalo
| - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 87 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Rajeev Chillakuru
- Persönliches Netzwerk